(E/Z)-4-HTA monohydrate

• Catalog No.: H5039
• M. F.: C24H24O5
• M. W.: 392.44436
• Purity: ≥90% (HPLC)

SYNONYMS

• IUPAC name: 2-{4-[1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl]phenoxy}acetic acid hydrate
• IUPAC Traditional name: 4-[1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl]phenoxyacetic acid hydrate
• Synonyms: 4-Hydroxytamoxifen acid; (E,Z)-2-[4-[1-(p-Hydroxyphenyl)-2-phenyl]-1-butenyl]phenoxyacetic acid

DATABASE IDS

• PubChem SID: 24724502

PROPERTIES

• Empirical Formula (Hill Notation): C24H22O4 · H2O
• Purity: ≥90% (HPLC)
• Apperance: solid
• Solubility: DMSO: >6 mg/mL
• GHS Signal Word: Warning
• GHS Hazard statements: H410
• European Hazard Symbols: Nature polluting (N)
• Personal Protective Equipment: Eyeshields, Gloves
• GHS Precautionary statements: P273-P501
• RID/ADR: UN 3077 9/PG 3
• Risk Statements: 50/53
• Safety Statements: 36/37-60-61
• Storage Temperature: 2-8°C
• Hazard Class: 9
• UN Number: 3077
• Packing Group: 3
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
4-hydroxytamoxifen acid is a preferred tamoxifen analog, a nonsteroidal estrogenic compound for use in estrogen replacement therapy, and specifically menopause therapy. The estrogen replacements are administered to patients as the free acid or a pharmaceutically acceptable salt in combination with pharmaceutical carriers to alleviate conditions associated with a low level of estrogen, including osteoporosis, premenstrual syndrome, vasomotor symptoms associated with menopause, atrophic vaginitis, Kraurosis vulvae, female hypogonadism, primary ovarian failure, excessive hair growth and prostatic cancer.

Description (简体中文)

Biochem/physiol Actions
4-hydroxytamoxifen acid is a preferred tamoxifen analog, a nonsteroidal estrogenic compound for use in estrogen replacement therapy, and specifically menopause therapy. The estrogen replacements are administered to patients as the free acid or a pharmaceutically acceptable salt in combination with pharmaceutical carriers to alleviate conditions associated with a low level of estrogen, including osteoporosis, premenstrual syndrome, vasomotor symptoms associated with menopause, atrophic vaginitis, Kraurosis vulvae, female hypogonadism, primary ovarian failure, excessive hair growth and prostatic cancer.